The Vision and Promise of CD46

Posts classified under: General

Search for:

Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma
Fortis Therapeutics Closes $18 Million Series A Financing to Advance New Antibody Drug Conjugate Therapies for the Treatment of Late-Stage Cancers
Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma